Novacyt S.A. (NCYT.L) Stock Price
£41 0.5%
to add to portfolio
AI Score

-
Alternative
5 -
Fundamental
2 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Novacyt S.A., AI stock picks, stock alerts and much more.
NCYT.L AI Stock Analysis
AI stock analysis for NCYT.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Novacyt S.A. (NCYT.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Novacyt S.A. (NCYT.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Novacyt S.A. (NCYT.L), currently trading at £41, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About NCYT.L

-
Novacyt S.
-
Symbol
NCYT.L
-
Market
LSE
-
Industry
Medical - Devices
-
Market Cap
29M
Similar Stocks
![]() |
Creo Medical Limited CREO.L |
£12.25 1% |
5 |
![]() |
Smith & Nephew SN.L |
£1100 0.8% |
7 |
![]() |
Belluscura BELL.L |
£0.75 3.5% |
4 |
![]() |
Surgical Innovations Group SUN.L |
£0.7 4.1% |
5 |
![]() |
Inspiration Healthcare Group IHC.L |
£22 4% |
4 |
NCYT.L Alternative Data
Web Traffic
Novacyt S.A. receives an estimated 3197 monthly visitors to novacyt.com.
-
Web Traffic
3197
-
Change from Previous Month
9.4%
-
3 Month Change
0.3%
-
YoY Change
0.3%
Twitter Followers
Novacyt S.A. has 2,777 Twitter Followers on its main Twitter (also known as X) account.
-
Twitter Followers
2777
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.6%
-
YoY Change
0.6%
Facebook Engagement
Novacyt S.A. has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
100%
Youtube Subscribers
Novacyt S.A. has 681 subscribers on its main Youtube channel, down by -0.3% over the last month.
-
Youtube Subscribers
681
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
0.9%
Job Postings
Novacyt S.A. has an estimated 1 open job postings, which is down -66.7% over the last month.
-
Job Postings
1
-
Daily Change
0%
-
1 Month Change
66.7%
-
3 Month Change
0%
LinkedIn Followers
8,112 are following Novacyt S.A. on LinkedIn, up by 4.2% over the last month.
-
LinkedIn Followers
8112
-
Daily Change
4.2%
-
1 Month Change
4.2%
-
3 Month Change
5.1%
Business Outlook
According to employee reviews, the business outlook among employees at Novacyt S.A. is 66 out of 100 (bullish).
-
Business Outlook
66
-
Change from Previous Month
0%
-
3 Month Change
1.5%
-
YoY Change
1.5%
LinkedIn Employees
According to LinkedIn, Novacyt S.A. has 63 employees, down by -6% over the last month.
-
LinkedIn Employees
63
-
Daily Change
6%
-
1 Month Change
6%
-
3 Month Change
7.4%
-
YoY Change
7.4%
News Mentions
Novacyt S.A. was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
Reddit Mentions
Novacyt S.A. has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
1 Month Change
0%
-
3 Month Change
0%
NCYT.L Financials
NCYT.L Key Metrics
-
Total Revenue
£5.2M
-
Net Income
-£8.8M
-
Earnings per Share
-£0.13
-
Free cash flow
-£9.1M
-
EBITDA
-£12M
-
EBITDA Ratio
-2.32944
-
Total Assets
£99.3M
NCYT.L 2-year Revenue & Income
NCYT.L 2-year Free Cash Flow
NCYT.L Technicals
NCYT.L SMA
NCYT.L RSI
FAQ
What's the current price of Novacyt S.A. (NCYT.L) Stock?
The price of an Novacyt S.A. (NCYT.L) share is £41.
What's the market cap of Novacyt S.A.?
The current market cap of Novacyt S.A. is 29M.
Should I buy or sell NCYT.L?
Novacyt S.A. shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Novacyt S.A. is better viewed as a hold or accumulate position while waiting for further developments.
Is Novacyt S.A. a good investment?
The current analysis of Novacyt S.A.'s fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Novacyt S.A.'s portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Novacyt S.A. (NCYT.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Novacyt S.A. stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Novacyt S.A. (NCYT.L) that investors often compare it to?
Novacyt S.A. (NCYT.L) is often compared to similar stocks such as Creo Medical Limited, Smith & Nephew, Belluscura, Surgical Innovations Group and Inspiration Healthcare Group.
What is the forecast for Novacyt S.A.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Novacyt S.A.'s stock price to be around £40.06 in 2026. Starting from the current price of £41, this represents a 2.3% change in price, indicating a neutral outlook for the stock.
How to buy Novacyt S.A. (NCYT.L) Stock?
Novacyt S.A. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Novacyt S.A. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.